


## PHARMACEUTICAL 2020

## Oncotelic Therapeutics Inc. Rank 112 of 362





## PHARMACEUTICAL 2020

## Oncotelic Therapeutics Inc. Rank 112 of 362

The relative strengths and weaknesses of Oncotelic Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Oncotelic Therapeutics Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 589% points. The greatest weakness of Oncotelic Therapeutics Inc. is the variable Other Net Income, reducing the Economic Capital Ratio by 61% points.

The company's Economic Capital Ratio, given in the ranking table, is -55%, being 248% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	273
Cost of Goods Sold	0
Intangible Assets	21,987
Liabilities, Current	6,783
Liabilities, Non-Current	0
Other Assets	1,377
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-2,327
Property and Equipment	48
Research and Development	1,372
Revenues	0
Selling, General and Administrative Expense	2,939

Output Variable	Value in 1000 USD
Assets	23,685
Liabilities	6,783
Expenses	4,311
Stockholders Equity	16,902
Net Income	-6,638
Comprehensive Net Income	-6,638
Economic Capital Ratio	-55%